Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)
Launched by EUROPEAN SOCIETY OF CUTANEOUS LUPUS ERYTHEMATOSUS E.V. · Jan 8, 2007
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Methods: A core set questionnaire has been developed in the course of the "European Society of Cutaneous Lupus Erythematosus (EUSCLE)", and a total of 40 patients (32 females, 8 males) in two centres, Germany and Sweden, were included in this study. Results: CLE was diagnosed in 39 individuals (5 with acute CLE, 10 with subacute CLE, 13 with chronic CLE, and 18 with intermittent CLE) and one individual presented with a systemic manifestation of the disease. Furthermore, disease onset and duration as well as activity and damage of skin lesions using a modified CLASI were examined. Interestin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • cutaneous lupus erythematosus confirmed by histological analysis
- • photoprovocation-test performed in advance
- • written informed consent available prior to any procedures
- Exclusion Criteria:
- • patients with conditions that are contrary to the above mentioned criteria
About European Society Of Cutaneous Lupus Erythematosus E.V.
The European Society of Cutaneous Lupus Erythematosus e.V. (ESCLE) is a dedicated organization focused on advancing the understanding and treatment of cutaneous lupus erythematosus through collaborative research, education, and clinical trials. Comprising a network of leading experts in dermatology and autoimmune diseases, ESCLE aims to foster innovation in patient care and improve outcomes for individuals affected by this condition. The society actively engages in promoting awareness, facilitating scientific exchange, and supporting the development of evidence-based practices within the field, ultimately striving to enhance the quality of life for patients suffering from cutaneous manifestations of lupus.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Muenster, Nrw, Germany
Patients applied
Trial Officials
Annegret Kuhn, MD
Principal Investigator
Universität Münster
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials